First positive phase III data for a gamma secretase inhibitor in desmoid tumours
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours
Neoadjuvant chemotherapy is on course to become standard treatment for selected high-risk soft tissue sarcomas but effects in low-risk disease are unclear
Despite age-specific difficulties, increased understanding of sarcoma biology is leading the way to the development of new treatment strategies
Proteomic research on sarcomas is only in its infancy, but it offers potential in terms of improved biological understanding, identification of new treatment targets and generating biomarkers for patient selection and prognosis prediction
2021 ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guidelines open the door to genetic testing but the search for new treatments continues
In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard
Continued efforts in patient selection, combination strategies and novel approaches may help to turn the tide for immunotherapeutics in sarcoma, according to Prof. Jean-Yves Blay
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
A growing body of evidence has identified Notch mutations as a potential target in adenoid cystic carcinoma (ACC), a rare type of salivary gland carcinoma
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.